About six months ago, I shared an update about my 83-year-old father:
healthunlocked.com/advanced...
Thank you all for your helpful responses. Here’s a brief update on where things stand today:
In July 2024, I returned to New Zealand, where my father lives, after he experienced a delirium episode that required hospitalization. His physical and cognitive decline since then has been significant.
Back in February 2024, he was an active and healthy man, playing tennis twice a week and table tennis. However, after starting androgen deprivation therapy (ADT) with the three-month Goserelin injection, his health began to deteriorate. While he initially responded well, by June 2024, he was experiencing severe fatigue, cognitive issues, and bone pain. Due to the side effects, his wife (my stepmother) decided against continuing with the second dose of ADT, prioritizing his quality of life.
Here are some key milestones in his journey:
February 2024: PSA was 65.
August 2024: PSA rose to 115. Radiation for bone pain was scheduled, but by the time of the appointment, his pain had subsided, and he was feeling better. The radiation oncologist referred him back to his GP for quarterly PSA testing.
November 2024: PSA was 90.
January 2025: PSA has now risen to 256, and he is experiencing significant bone pain again.
In August 2024, the oncologist suggested that if his PSA increased, he could consider a one-month dose of ADT (Goserelin) and palliative radiation for pain. However, I suspect my stepmother is reluctant to revisit ADT due to the severe side effects he experienced. I remain hopeful that palliative radiation will help manage his pain.
It’s clear that he’s nearing the end of his journey. As his son, I’d like him to consider treatments that could prolong his life, such as ADT, but I understand the focus is now on comfort and quality of life. I don’t know much about other treatments, such as abiraterone. My impression is that without long-term ADT, options like abiraterone or radiopharmaceutical therapy may not be viable. Additionally, radiopharmaceutical therapy is not covered in New Zealand, and the cost seems disproportionate to the minimal benefits in longevity.
We have an appointment with the radiation oncologist tomorrow. My stepmother has already decided to focus on palliative care rather than aggressive treatments. Over the past three months, his dementia and mental cognition have significantly declined.
I wanted to share where we are now and thank you all for your support and feedback.